Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Azurrx Biopharma Inc (AZRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
AzurRx BioPharma Announces Successful Phase IIa Trial of MS1819-SD in Exocrine Pancreatic Insufficiency

AzurRx BioPharma, Inc. (NASDAQ:AZRX) ("AzurRx" or the "Company"), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced, in partnership...

AZRX : 2.58 (-2.27%)
AzurRx Announces Appointment of Dr. James Pennington as Chief Medical Officer

AzurRx BioPharma, Inc. (NASDAQ:AZRX) ("AzurRx" or the "Company"), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced the appointment...

AZRX : 2.58 (-2.27%)
AzurRx BioPharma Announces Pricing of $10.4 Million Public Offering of Common Stock

AzurRx BioPharma (NASDAQ:AZRX), ("AzurRx" or the "Company"), today announced the pricing of an underwritten public offering of 4,160,000 shares of its common stock at an offering price of $2.50 per share....

AZRX : 2.58 (-2.27%)
AzurRx BioPharma and Mayoly-Spindler Announce Additional Positive Interim Data for MS1819-SD Phase II in Exocrine Pancreatic Insufficiency (EPI)

AzurRx BioPharma Inc. (NASDAQ:AZRX) ("AzurRx" or the "Company"), today provided an update on the first nine treated patients in its ongoing Phase IIa trial of MS1819-SD, a recombinant lipase, for the treatment...

AZRX : 2.58 (-2.27%)
AzurRx BioPharma Announces Positive Preclinical Data with AZX1103

-- Company is developing AZX1103 for the prevention of nosocomial infections induced by administration of several classes of antibiotics

AZRX : 2.58 (-2.27%)
Stock Market Manager Announces the Hosting of Research Coverage of AzurRx, Biopharma, Inc. (NASDAQ: AZRX) by Trickle Research LLC

CLEARWATER, FL / ACCESSWIRE / March 2, 2018 / The AzurRx Biopharma, Inc. (NASDAQ: AZRX) research report is available on Stock Market Manager (smm.global):

AZRX : 2.58 (-2.27%)
AzurRx BioPharma to Present at the 30th Annual ROTH Conference (March 12th)

AzurRx BioPharma, Inc. (NASDAQ:AZRX) ("AzurRx" or the "Company"), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, announced today the Company...

AZRX : 2.58 (-2.27%)
AzurRx BioPharma Announces Enrollment of Three New Patients for its Phase IIa Study of MS1819-SD

AzurRx BioPharma, Inc. (NASDAQ:AZRX) ("AzurRx" or the "Company"), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, announced today that in...

AZRX : 2.58 (-2.27%)
AzurRx BioPharma to Present at the 2018 BIO CEO & Investor Conference (February 12th)

AzurRx BioPharma, Inc. (NASDAQ:AZRX) ("AzurRx" or the "Company"), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, announced today the Company...

AZRX : 2.58 (-2.27%)
SeeThruEquity Initiates Coverage on AzurRx BioPharma, Inc. (NASDAQ CM: AZRX) with a Price Target of $10.00

NEW YORK, NY / ACCESSWIRE / January 30, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has...

AZRX : 2.58 (-2.27%)
AzurRx BioPharma Announces Receipt of Required Approvals to Add French Clinical Site for its Phase IIa Study of MS1819-SD for Exocrine Pancreatic Insufficiency

AzurRx BioPharma, Inc. (NASDAQ:AZRX) ("AzurRx" or the "Company"), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, announced today that in...

AZRX : 2.58 (-2.27%)
AzurRx BioPharma Receives $2 Million in Proceeds from Exercise of Warrants

AzurRx BioPharma, Inc. (NASDAQ:AZRX) ("AzurRx" or the "Company"), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, announced today that it...

AZRX : 2.58 (-2.27%)
AzurRx BioPharma and Mayoly Spindler Announce MS1819-SD Investigational Medicinal Product Dossier (IMPD) Submission

AzurRx BioPharma Inc. (NASDAQ:AZRX) ("AzurRx" or the "Company"), announced the submission of an Investigational Medicinal Product Dossier (IMPD) for its lead product MS1819-SD, a recombinant lipase for...

AZRX : 2.58 (-2.27%)
AzurRx Announces Addition of Dr. Vern Lee Schramm to the Board of Directors

AzurRx BioPharma, Inc. (NASDAQ:AZRX) ("AzurRx" or the "Company") a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases today announced the appointment...

AZRX : 2.58 (-2.27%)
AzurRx BioPharma and Mayoly-Spindler Announce Positive MS1819-SD Phase II Data in Exocrine Pancreatic Insufficiency (EPI)

AzurRx BioPharma Inc.(NASDAQ:AZRX) ("AzurRx" or the "Company"), today provided an update on the first six treated patients in its ongoing Phase IIa trial of MS1819-SD, a recombinant lipase, for the treatment...

AZRX : 2.58 (-2.27%)
AzurRx Announces Appointment of Maged Shenouda as Chief Financial Officer

AzurRx BioPharma, Inc. (NASDAQ:AZRX) ("AzurRx" or the "Company") a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases today announced the appointment...

AZRX : 2.58 (-2.27%)
AzurRx BioPharma to Present at the Rodman & Renshaw 19th Annual Global Investment Conference on September 12

AzurRx BioPharma, Inc. (NASDAQ:AZRX) ("AzurRx" or the "Company"), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, announced today the Company...

AZRX : 2.58 (-2.27%)
AzurRx Reaches 6th Patient Enrollment of Phase IIa Trial of MS1819 for Treatment of Exocrine Pancreatic Insufficiency Associated with Chronic Pancreatitis

Results on First Six Patients Expected in September

AZRX : 2.58 (-2.27%)
BUYINS.NET: AZRX SqueezeTrigger Price is $4.07. There is $93,257 That Short Sellers Still Need To Cover.

BUYINS.NET / www.buyins.net is monitoring AzurRX Biopharma (NASDAQ:AZRX) in real time and just received an alert that AZRX is crossing above its primary SqueezeTrigger Price, the price that a short squeeze...

AZRX : 2.58 (-2.27%)

Van Meerten Stock Picks

5 Terrific Mid Caps
In this roller coaster market I wanted to find Mid Cap stocks that had consistent price appreciation over the last 6 month period.
EHC -0.38 , FTNT +0.53 , CAKE -0.45 , PLT -0.28 , AEO -0.65
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.
Free Commodities Newsletter

Get prepared for your trading day with

Barchart's Commodity Futures Morning Update Email

InsideFutures Commentary

InsideFutures weekly newsletter features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Friday morning to your inbox.

Agricharts Market Commentary

Today's Commentary

Corn futures closed the week with most contracts 3 to 4 cents higher on Friday. Nearby September was up 4.1% since last Friday, with higher closes every day this week. Solid exports and drier weather fueled some bottom picking and short covering acti...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar